Understanding Chronic Kidney Disease Stage 3 (CKD3 or ckd stage 3) requires accurate clinical documentation and medical coding. This resource provides information on CKD Stage 3 diagnosis, including moderate CKD management, relevant healthcare guidelines, and best practices for medical coding and documentation. Learn about the key indicators, treatment options, and clinical considerations for Chronic Kidney Disease Stage 3 to ensure proper patient care and accurate medical records.
Also known as
Chronic kidney disease, stage 3
Moderate decrease in kidney function.
Chronic kidney disease
Long-term progressive loss of kidney function.
Hypertensive diseases
High blood pressure, a common cause of CKD.
Diabetes mellitus
Another leading cause of chronic kidney disease.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the documented diagnosis Chronic Kidney Disease Stage 3?
Yes
Is there documentation of cause?
No
Do not code as CKD Stage 3. Review documentation for alternative diagnosis.
When to use each related code
| Description |
|---|
| Moderate kidney damage, GFR 30-59 mL/min. |
| Mild kidney damage, GFR 60-89 mL/min. |
| Severe kidney damage, GFR 15-29 mL/min. |
Lack of sufficient documentation to support CKD Stage 3 diagnosis, leading to potential coding errors and denials. Requires specific lab results and clinical findings.
Coding CKD Stage 3 requires precise documentation of GFR and albuminuria levels. Unspecified CKD coding may lead to downcoding and lost revenue.
CKD3 often coexists with conditions like hypertension and diabetes. Failing to capture these comorbidities impacts risk adjustment and reimbursement.
Q: What are the most effective strategies for managing proteinuria in patients with chronic kidney disease stage 3 (CKD3)?
A: Managing proteinuria in CKD3 is crucial for slowing disease progression. Evidence-based strategies include optimizing blood pressure control, primarily with ACE inhibitors or ARBs, and implementing dietary protein restriction tailored to the patient's individual needs and glomerular filtration rate (GFR). Consider implementing dual RAAS blockade in appropriate patients. Explore how SGLT2 inhibitors can further reduce proteinuria and offer cardiorenal protection. Regular monitoring of proteinuria through urine albumin-to-creatinine ratio (UACR) is essential for assessing treatment effectiveness. Learn more about the latest KDIGO guidelines for CKD management.
Q: How can clinicians differentiate between chronic kidney disease stage 3a and 3b, and what are the key implications for treatment and monitoring?
A: Differentiating between CKD3a and 3b hinges on the estimated glomerular filtration rate (eGFR). CKD3a is defined by an eGFR between 45 and 59 mL/min/1.73m2, while CKD3b falls between 30 and 44 mL/min/1.73m2. This distinction is critical because it influences treatment decisions and monitoring frequency. Patients in CKD3b, with lower eGFR, require closer monitoring for complications like anemia, mineral bone disorders, and faster disease progression. Consider implementing strategies to manage cardiovascular risk factors more aggressively in CKD3b patients. Explore the latest research on the use of non-calcium-based phosphate binders and erythropoiesis-stimulating agents in this patient population.
Patient presents with chronic kidney disease stage 3 (CKD3, moderate CKD), confirmed by estimated glomerular filtration rate (eGFR) between 30 and 59 mL/min/1.73m2 persisting for greater than three months. Relevant clinical findings include (but are not limited to) elevated creatinine levels, proteinuria, and or other markers of kidney damage. Patient history includes [mention specific relevant history, e.g., hypertension, diabetes, family history of kidney disease]. Current medications include [list medications]. Physical exam reveals [document relevant findings, e.g., normal heart sounds, no edema]. Assessment includes chronic kidney disease stage 3 (CKD stage 3) with associated [list comorbidities, e.g., hypertension, anemia]. Plan includes monitoring of renal function (eGFR and creatinine), blood pressure management, management of underlying conditions contributing to CKD, patient education on dietary modifications (renal diet, protein restriction, potassium and phosphorus control), and medication management as indicated. Referral to nephrology is considered. ICD-10 code N18.3 (Chronic kidney disease, stage 3) is applicable. Further evaluation and monitoring are warranted to assess disease progression and adjust treatment accordingly. Patient understands the plan and agrees to follow up.